November 14, 2024 11:12 AM EST
R&D

New Zealand clears first clin­i­cal tri­al of epi­ge­net­ic edit­ing for he­pati­tis B

Lei Lei Wu

News Reporter

Tune Ther­a­peu­tics an­nounced Thurs­day that New Zealand health au­thor­i­ties are al­low­ing the com­pa­ny to study its ex­per­i­men­tal epi­ge­net­ic edit­ing ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times